XmAb13676-01 (Chiltern CIL 36858) - A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb®13676 in Patients with CD20-Expressing Hematologic Malignancies

IRB/UVA Tracking #
20464
Contact First Name

Erica Stallard

Contact Email
Phase
I
Primary purpose
Treatment
Cancer PI
Craig Portell
Status
OPEN TO ACCRUAL